← Back to Search

Radiation Therapy

Radiation Therapy for Metastatic Cancer

N/A
Recruiting
Led By Atif Khan, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks from baseline
Awards & highlights
No Placebo-Only Group

Summary

This trial compares two types of radiation therapy to see which is more effective and how it affects the tumor's ability to be attacked by the immune system. #LRTvsSBRT

Who is the study for?
This trial is for adults with advanced solid tumors needing palliative radiation, who have at least one other site of metastasis suitable for radiation. They must be in good physical condition (ECOG 0 or 1) and understand the study's risks. It's not for those previously radiated at the same sites, with uncontrolled conditions like infections or diabetes, on steroids, pregnant/breastfeeding, having a second active cancer, or unable to follow study procedures.
What is being tested?
The trial compares two types of radiation therapy: Lattice Radiation Therapy (LRT) and standard Stereotactic Body Radiation Therapy (SBRT). The goal is to see which method is more effective and how they influence immune cells' ability to attack tumor cells.
What are the potential side effects?
Radiation therapy side effects can include skin reactions where treated, fatigue, nausea, pain at treatment site. Long-term effects might involve damage to nearby organs/tissues depending on where the radiation targets.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks from baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks from baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall Response Rate (ORR)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Participants with metastatic solid tumorsExperimental Treatment2 Interventions
Participants will have metastatic solid tumors and at least two sites of measurable extra-cranial disease
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Stereotactic body radiotherapy
2021
Completed Phase 4
~840

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,969 Previous Clinical Trials
597,333 Total Patients Enrolled
78 Trials studying Melanoma
16,188 Patients Enrolled for Melanoma
Varian Medical SystemsIndustry Sponsor
61 Previous Clinical Trials
3,607 Total Patients Enrolled
Atif Khan, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
3 Previous Clinical Trials
125 Total Patients Enrolled

Media Library

Lattice Radiation Therapy (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05837767 — N/A
Melanoma Research Study Groups: Participants with metastatic solid tumors
Melanoma Clinical Trial 2023: Lattice Radiation Therapy Highlights & Side Effects. Trial Name: NCT05837767 — N/A
Lattice Radiation Therapy (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05837767 — N/A
~14 spots leftby Jul 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top